Traphagen Investment Advisors 13F: New $204K Stake in MDT

Traphagen Investment Advisors has opened a new position in Medtronic plc (NYSE: MDT), buying 2,361 shares of the healthcare company. The move was revealed in a Form 13F filing with the Securities and Exchange Commission on October 14, 2026. Because 13F reports look backward, these numbers reflect holdings at the close of the quarter and might not match the firm's exact spot trades today. At the reported value of $203,704, the new holding represents a fresh stake for the fund.

What Changed in Traphagen Investment Advisors's Medtronic Position

The firm started its investment in Medtronic during the period by acquiring 2,361 shares. With zero shares prior, this new buy gives the fund a direct position in the medical device maker valued at $203,704.

Other Institutional Activity in Medtronic

Other large funds were busy adjusting their own Medtronic positions around the same time. Blackrock Inc. grew its holdings by 837,556 shares, ending with 114,020,787 shares worth about $10,803,469,568. Vanguard Capital Management LLC added 483,334 shares to hold 83,816,735 shares valued at about $7,941,635,641. State Street Corporation increased its stake by 1,660,767 shares, finishing with 63,399,315 shares worth roughly $6,007,085,096. Vanguard Portfolio Management LLC lifted its position by 608,811 shares to reach 34,059,967 shares valued at about $3,227,181,873. Finally, Geode Capital Management, LLC grew its holdings by 1,456,872 shares, ending with 30,192,015 shares worth about $2,860,693,421.

Medtronic plc Stock Down 1.0%

Medtronic shares recently traded around $94.46. That price puts the stock up about 4.1% above its 50-day moving average of $90.71 and about 7.0% above its 200-day moving average of $88.31. The stock sits about 11.2% below its 52-week high of $106.33 and roughly 28.9% above its 52-week low of $73.31.

Recent Earnings

Medtronic reported trailing twelve-month revenue of $37.54 billion alongside earnings of $4.07 per share. The company posted a net profit margin of 13.9% and a return on equity of 10.6%. Its next earnings report is scheduled for November 17, 2026.

Dividend

Medtronic pays an annual dividend of $2.88 per share, giving it a dividend yield of 3.02%. The company allocates about 70.0% of its earnings toward its dividend payout.

Insider Buying and Selling at Medtronic plc

Company insiders made several transactions before the filing. On June 8, 2026, officer Harry Skip Kiil sold 4,189 shares for a total value of $336,965. Later, on July 8, 2026, officer Matthew R. Walter sold 3,102 shares at an average price of $83.15, totaling $257,931. On September 16, 2026, Harry Skip Kiil sold another 1,483 shares at an average price of $93.65 for a total value of $138,883.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock in recent weeks. On September 2, 2026, Truist Securities reiterated a hold rating with a $99.00 price target. UBS maintained a buy rating on September 3, 2026, raising its target from $100.00 to $110.00. TD Cowen kept a buy rating and a $110.00 target on September 30, 2026. Barclays initiated coverage with an equal-weight rating and a $95.00 target on October 7, 2026. BTIG maintained a buy rating on October 12, 2026, while adjusting its target from $100.00 to $99.00. Medtronic currently holds a consensus buy rating from 25 analysts, with a mean price target of $104.40.

About Medtronic

Medtronic plc designs and manufactures device-based medical therapies for healthcare systems, doctors, and patients worldwide. Based in Galway, Ireland, the company operates across three main segments covering cardiovascular solutions, neuroscience equipment, and medical surgical products. Institutional filings like Traphagen's new stake highlight ongoing portfolio adjustments in major healthcare names.

Bottom Line

Investors will look to Medtronic's upcoming earnings report on November 17, 2026 to gauge the company's financial health. Because 13F filings lag behind real-time trading, market watchers should review subsequent SEC disclosures for any further updates on Traphagen's position. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.